Related Experiment Video
Updated: Jun 19, 2025
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
9.8K
PharmVar GeneFocus: CYP2A6
Alec W R Langlois1,2, Meghan J Chenoweth1,2,3, David Twesigomwe4
1Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
Clinical Pharmacology and Therapeutics
|July 25, 2024
Summary
Genetic variations in the CYP2A6 gene impact nicotine and drug metabolism, affecting treatment efficacy and safety. Understanding these CYP2A6 variations is crucial for accurate pharmacogenetic predictions.
Area of Science:
- Pharmacogenomics
- Genetics
- Biochemistry
Background:
- The CYP2A6 gene is highly polymorphic and crucial for metabolizing nicotine and various drugs.
- Genetic variations in CYP2A6 can significantly alter enzyme function, impacting drug efficacy and safety.
- Accurate genotype determination is essential for predicting patient response to medications.
Purpose of the Study:
- To provide an overview of the clinical significance of CYP2A6 genetic variation and function.
- To highlight challenges in identifying and characterizing allelic variations within the CYP2A6 gene.
- To emphasize the importance of accurate CYP2A6 genotyping for phenotype prediction.
Main Methods:
- Review of existing literature on CYP2A6 genetic variation.
- Analysis of nomenclature and characterization of CYP2A6 alleles.
- Discussion of clinical implications of CYP2A6 polymorphisms.
Main Results:
- CYP2A6 genetic variations are clinically significant for drug metabolism.
- Challenges exist in the precise identification and characterization of CYP2A6 allelic variations.
- Accurate genotyping is a prerequisite for predicting CYP2A6 phenotype status.
Conclusions:
- Understanding CYP2A6 genetic variation is vital for personalized medicine.
- Further research is needed to refine methods for characterizing complex pharmacogene variations.
- Accurate CYP2A6 genotype-phenotype correlation is key to optimizing drug therapy.
Related Concept Videos
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
113
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
113
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
126
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
126
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
36
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
36
01:14Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
01:06Carrier-Mediated Transport
322
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
322
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
137
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
137